Testing whether the circulating tumor cells display higher phospho-Erk levels than those composing respective primary ErbB2-negative tumors would represent a promising direction of the studies aimed at verifying the role of Mek/Erk activity in ErbB2 expression in breast cancer patients. This evidence concerns the gene MAPK1 and neoplasm.